Cancer Immunology
Author: Ronald B Herberman
Publisher:
Published: 1986-02-01
Total Pages: 244
ISBN-13: 9781461326304
DOWNLOAD EBOOKRead and Download eBook Full
Author: Ronald B Herberman
Publisher:
Published: 1986-02-01
Total Pages: 244
ISBN-13: 9781461326304
DOWNLOAD EBOOKAuthor: Ronald B. Herberman
Publisher: Springer Science & Business Media
Published: 2012-12-06
Total Pages: 238
ISBN-13: 146132629X
DOWNLOAD EBOOKThis volume is the second in the 'Cancer Treatment and Research' series focussing on basic and clinical tumor immunology. It has a rather different focus or emphasis from that of the first volume, published two years ago. That work (Basic and Clinical Tumor Immunology, R.B. Herberman, ed., Martinus Nijhoff Publishers, 1983) devoted considerable attention to up dated summaries in various areas of classical tumor immunology: specific antitumor immunity, the immunologic competence of cancer patietns, char acterization of human tumor-associated antigens, the ability to propagate specifically immune T cells in culture in the presence of interleukin 2, and the use of such cells for adoptive immunotherapy of established tumors. of evidence concerning the immune However, it also reviewed the status surveillance hypothesis and pointed out the need to consider non-T cell mediated mechanisms of host resistance. In particular, one chapter sum marized information on the role of macrophages in host resistance against tumors. The present volume continues to emphasize one of the major themes of the first volume, innovative approaches to the therapy of cancer. It involves contributions from leading investigators on several primary types of therapeutic interventions related to monoclonal antibodies, the col laboration of monoclonal antibodies with macro phages to mediate antibody dependent cellular cytotoxicity, lymphokines, tumor vaccines, and natural killer cells. It also has an up-to-date summary of the immunologic aspects of the exciting and promising work being performed on human T cell leukemia virus in the laboratory of Dr. Robert Gallo.
Author: Ronald B. Herberman
Publisher: Springer Science & Business Media
Published: 1986-02-28
Total Pages: 250
ISBN-13: 9780898387575
DOWNLOAD EBOOKThis volume is the second in the 'Cancer Treatment and Research' series focussing on basic and clinical tumor immunology. It has a rather different focus or emphasis from that of the first volume, published two years ago. That work (Basic and Clinical Tumor Immunology, R.B. Herberman, ed., Martinus Nijhoff Publishers, 1983) devoted considerable attention to up dated summaries in various areas of classical tumor immunology: specific antitumor immunity, the immunologic competence of cancer patietns, char acterization of human tumor-associated antigens, the ability to propagate specifically immune T cells in culture in the presence of interleukin 2, and the use of such cells for adoptive immunotherapy of established tumors. of evidence concerning the immune However, it also reviewed the status surveillance hypothesis and pointed out the need to consider non-T cell mediated mechanisms of host resistance. In particular, one chapter sum marized information on the role of macrophages in host resistance against tumors. The present volume continues to emphasize one of the major themes of the first volume, innovative approaches to the therapy of cancer. It involves contributions from leading investigators on several primary types of therapeutic interventions related to monoclonal antibodies, the col laboration of monoclonal antibodies with macro phages to mediate antibody dependent cellular cytotoxicity, lymphokines, tumor vaccines, and natural killer cells. It also has an up-to-date summary of the immunologic aspects of the exciting and promising work being performed on human T cell leukemia virus in the laboratory of Dr. Robert Gallo.
Author: Paul D. Rennert
Publisher: Springer
Published: 2016-05-30
Total Pages: 285
ISBN-13: 3319298275
DOWNLOAD EBOOKCancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
Author: PATHAN AZHER KHAN
Publisher: Pristyn Research Solutions
Published: 2024-05-16
Total Pages: 54
ISBN-13: 8197170134
DOWNLOAD EBOOKThis book comprehensively examines the landscape of immunotherapeutic modalities in cancer treatment, with a specific focus on Chimeric Antigen Receptor (CAR) T-cell therapy, immune checkpoint inhibitors, and other innovative approaches. The CAR T-cell therapy represents a groundbreaking approach wherein T-cells are genetically engineered to recognize and eradicate tumor cells expressing specific antigens. The book briefly discussed the clinical applications and challenges associated with CAR T-cell therapy, case studies highlighting its remarkable efficacy in malignancies, and emerging potential in solid tumors. Additionally, immune checkpoint inhibitors have transformed the treatment of various cancers by disrupting inhibitory signalling pathways and reinvigorating antitumor immune responses. This book explores the mechanisms, clinical efficacy, and challenges of immune checkpoint blockade, including strategies to overcome resistance and improve patient outcomes. Furthermore, it promises other innovative immunotherapeutic strategies, such as tumor vaccines, cytokine therapies, and adoptive cell transfer. Personalized Approaches emphasize their potential synergies and future directions in combination with existing modalities. Overall, this book provides insights into the evolving landscape of cancer immunotherapy, emphasizing the significant strides made in improving patient outcomes and the ongoing efforts to optimize treatment efficacy and durability while minimizing adverse effects.
Author: Azhar ul Haque Sario
Publisher: tredition
Published: 2024-08-30
Total Pages: 189
ISBN-13: 3384338138
DOWNLOAD EBOOKUnlock the future of cancer treatment with "Immunotherapy Cancer Battle: Innovative Approaches for Success." This comprehensive guide dives deep into the revolutionary world of cancer immunotherapy, exploring the cutting-edge strategies and breakthroughs that are reshaping how we combat this relentless disease. But this book isn't just about the successes—it's also about the ongoing challenges and innovations in the field. You'll explore how scientists and clinicians are continually pushing the boundaries, combining immunotherapies with traditional treatments like chemotherapy and radiation to maximize efficacy. You'll delve into the world of tumor-infiltrating lymphocytes (TILs) and their potential for personalized treatment, as well as the promise of cancer vaccines that could one day prevent or treat cancers with unparalleled precision. Ever wondered how viruses might be used to fight cancer? You'll find out in the chapter on oncolytic virus therapy, where viruses are re-engineered to selectively infect and destroy cancer cells. Plus, you'll read about the exciting developments in adoptive cell transfer (ACT) therapies, including T-cells, natural killer (NK) cells, and cytokine-induced killer (CIK) cells, all working together to diversify and strengthen our immune responses. The book also covers innovative strategies like bispecific antibodies, which simultaneously engage two different targets, and next-generation immune checkpoints that go beyond PD-1 and CTLA-4 to offer new hope for patients. You'll gain insight into the complexities of the tumor microenvironment and how modulating it can enhance the effectiveness of immunotherapies, creating a more hostile environment for cancer to thrive. And that's not all. "Immunotherapy Cancer Battle" takes you through the futuristic applications of nanotechnology and epigenetic modulation in cancer treatment, showcasing how these cutting-edge fields are being harnessed to boost immune responses and deliver therapies more precisely than ever before. You'll discover the potential of precision immunotherapy, which tailors treatments based on individual genetic and molecular profiles, and the role of artificial intelligence in optimizing these personalized strategies. Whether you are a medical professional, researcher, or someone affected by cancer, this book is an invaluable resource that not only informs but inspires. With its comprehensive coverage and forward-looking insights, "Immunotherapy Cancer Battle: Innovative Approaches for Success" is more than just a book—it's a blueprint for the future of cancer treatment. Join us in exploring these pioneering frontiers and envision a world where cancer is no longer a death sentence but a disease we can outsmart, treat, and one day, perhaps, completely eradicate.
Author: Mansoor M. Amiji
Publisher: Academic Press
Published: 2021-08-18
Total Pages: 550
ISBN-13: 012823637X
DOWNLOAD EBOOKDelivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO
Author: Cedrik Michael Britten
Publisher: Springer
Published: 2014-04-23
Total Pages: 243
ISBN-13: 3319051040
DOWNLOAD EBOOKThis book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Author: Joseph Lustgarten
Publisher: Springer Science & Business Media
Published: 2009-10-09
Total Pages: 340
ISBN-13: 1441901701
DOWNLOAD EBOOKStimulation of the immune system’s ability to control and destroy tumors cont- ues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering every aspect of immune therapy but rather focuses on the novelty of cancer immune therapy in an attempt to give readers an opportunity to absorb the new aspects of immune therapy from a single source. In this regard, three areas were selected: cytokine immune therapy, cell-based immune therapy, and targeted immune therapy. In each of these three sections, only the novel aspects of immune therapy were described instead of attempting to cover any historical achievement. In the first section, Cytokine Immune Therapy, the IL12 family, IL18, IL21, IL24, IL28, and IL29 were emphasized in regard to the an- tumor function and application in treating tumors. Most of these selected cyt- ines were discovered in last 10 years. In the second section, Cell-based Immune Therapy, the focus was engineering potent immune regulatory or effector cells such as dendritic cells, T cells, and stem cells. Cell engineering design is primarily based on the increased understanding of the interaction of tumor antigen-presenting cells, antigen- specific effector cells, and the tumor microenvironment.
Author:
Publisher: Academic Press
Published: 2019-06-13
Total Pages: 400
ISBN-13: 0128170239
DOWNLOAD EBOOKImmunotherapy of Cancer, Volume 143, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Contributions from leading experts in the field make this a must have update on the topic. Provides that latest information on cancer research Offers outstanding and original reviews on a range of cancer research topics Serves as an indispensable reference for researchers and students alike